Effect of Testosterone on Insulin Sensitivity in Men with Idiopathic Hypogonadotropic Hypogonadism

Naharci, Mehmet İlkin; Pinar, Murat; Bolu, Erol; Olgun, Abdullah

doi:10.4158/ep.13.6.629

Cited by 64 publications

(59 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, there is hardly enough data about the effects of standard testosterone regimens on young, previously untreated CHH patients without confounders. Two recent reports performed in small groups mention that testosterone supplementation improves insulin resistance without significantly affecting the blood lipids, arterial blood pressure or WC (23,24). However, our results do not support these data and show increased WC, systolic blood pressure and decreased total and HDL cholesterol levels in the study group.…”

Section: Discussioncontrasting

confidence: 57%

“…In this regard, the data from patients with CHH are of utmost importance, as they may reflect the unconfounded effects of low testosterone levels on metabolic profiles. To our knowledge, there are only two small studies, both of which report higher fasting glucose and insulin levels in young men with CHH, without mentioning the other components of MS (23,24). Thus, our data are noteworthy as they show poor metabolic parameters in a sizeable group of treatment-naïve patients with CHH, mentioning that hypogonadism can cause MS even in very young ages.…”

Section: Discussionmentioning

confidence: 78%

“…Thus, the unconfounded data of the patients with congenital hypogonadal hypogonadism (CHH) are of utmost importance, as they can provide information about the effects of low testosterone levels on metabolic profiles. High fasting glucose and insulin levels in young men with CHH (23,24) were reported in two small studies. However, there is no data about the other components of MS in this specific population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

Sönmez¹,

Haymana²,

Bolu³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: The relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or chronic metabolic disorders. So far, there has been no data about the presence of MS in young hypogonadal patients. Also, there is controversial data about the metabolic effects of testosterone replacement therapy. We investigated the frequency of MS in treatment-naïve, young men with congenital hypogonadal hypogonadism (CHH). We also searched for the effect of testosterone replacement on the metabolic profiles of this specific patient group. Design: Retrospective analysis. Methods: A total of 332 patients (age 21.68G2.09 years) were enrolled. The control group included 395 age-and body mass index (BMI)-matched healthy young men (age 21.39G1.49 years). Standard regimen of testosterone esters (250 mg/3 weeks) was given to 208 patients. Results: MS was more prevalent in CHH (P!0.001) according to healthy controls. The patients had higher arterial blood pressure, waist circumference (WC), triglyceride (P!0.001 for all), fasting glucose (PZ0.02), fasting insulin (PZ0.004), homeostatic model assessment of insulin resistance (HOMA-IR) (PZ0.002) and lower high density lipoprotein (HDL) cholesterol (P!0.001) levels. After 5.63G2.6 months of testosterone treatment, the BMI, WC (P!0.001 for both), systolic blood pressure (PZ0.002) and triglyceride level (PZ0.04) were increased and the total and HDL cholesterol levels were decreased (PZ0.02 and P!0.001 respectively). Conclusions: This study shows increased prevalence of MS and unfavorable effects of testosterone replacement in young patients with CHH. Long-term follow-up studies are warranted to investigate the cardiovascular safety of testosterone treatment in this specific population.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 78%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

Sönmez¹,

Haymana²,

Bolu³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…It has not been clarified if the low levels of testosterone are the cause or the consequence of obesity and insulin resistance. In severe hypogonadism, for example, idiopathic hypogonadotropic hypogonadism, testosterone therapy improved insulin sensitivity (Naharci et al 2007). Theoretically, testosterone may have the potential to improve or deteriorate insulin sensitivity.…”

Section: Introductionmentioning

confidence: 99%

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Frederiksen

Højlund

Hougaard

et al. 2011

AGE

115

View full text Add to dashboard Cite

The indication for testosterone therapy in aging hypogonadal men without hypothalamic, pituitary, or testicular disease remains to be elucidated. The aim of this study was to investigate the effect of testosterone therapy on insulin sensitivity, substrate metabolism, body composition, and lipids in aging men with low normal bioavailable testosterone levels using a predefined cutoff level for bioavailable testosterone. A randomized, double-blinded, placebocontrolled study of testosterone treatment (gel) was done on 38 men, aged 60-78 years, with bioavailable testosterone <7.3 nmol/l and a waist circumference >94 cm. Insulin-stimulated glucose disposal (Rd) and substrate oxidation were assessed by euglycemic hyperinsulinemic clamps combined with indirect calorimetry. Lean body mass (LBM) and total fat mass (TFM) were measured by dual x-ray absorptiometry, and serum total testosterone was measured by tandem mass spectrometry. Bioavailable testosterone was calculated. Coefficients (b) represent the placebo-controlled mean effect of intervention. LBM (b=1.9 kg, p=0.003) increased while HDL-cholesterol (b=−0.12 mmol/l, p=0.043) and TFM decreased (b=−1.2 kg, p=0.038) in the testosterone group compared to placebo. Basal lipid oxidation (b=5.65 mg/min/m 2 , p=0.045) increased and basal glucose oxidation (b=−9.71 mg/min/m 2 , p = 0.046) decreased in response to testosterone therapy even when corrected for changes in LBM. No significant changes in insulin-stimulated Rd was observed (b=−0.01mg/min/m 2 , p=0.92). Testosterone therapy increased muscle mass and lipid oxidation in aging men with low normal bioavailable testosterone levels; however, our data did not support an effect of testosterone on whole-body insulin sensitivity using the euglycemic hyperinsulinemic clamp technique.

show abstract

“…Boyanov et al also showed that men with T2DM receiving three months of testosterone supplementation had decreased fasting glucose, postprandial glucose, mean daily glucose and HbA1c values, compared with baseline in men with T2DM (13 testosterone treatment in insulin-dependent hypogonadal patients improved the glycaemic control and reduced their insulin dosages by a mean of seven units (14). Naharci et al also had demonstrated that long term testosterone therapy can improve the insulin sensitivity and body composition parameters, especially the body fat mass (15).…”

Section: Introductionmentioning

confidence: 99%

Serum testosterone in males with newly diagnosed type 2 diabetes mellitus and microvascular complications

Bajaj

Srivastava

Varma

et al. 2016

Sri Lanka J. Diabetes Endocrinol. Metab.

View full text Add to dashboard Cite

Effect of Testosterone on Insulin Sensitivity in Men with Idiopathic Hypogonadotropic Hypogonadism

Cited by 64 publications

References 29 publications

Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Serum testosterone in males with newly diagnosed type 2 diabetes mellitus and microvascular complications

Contact Info

Product

Resources

About